IUPAC/Chemical Name
12-[(Adamantan-1-ylcarbamoyl)amino]dodecanoic acid
InChi Key
XLGSEOAVLVTJDH-UHFFFAOYSA-N
InChi Code
InChI=1S/C23H40N2O3/c26-21(27)10-8-6-4-2-1-3-5-7-9-11-24-22(28)25-23-15-18-12-19(16-23)14-20(13-18)17-23/h18-20H,1-17H2,(H,26,27)(H2,24,25,28)
SMILES Code
O=C(O)CCCCCCCCCCCNC(NC12CC3CC(C2)CC(C3)C1)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Preparing Stock Solutions
The following data is based on the
product
molecular weight
392.58
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Piotrowski J, Jędrzejewski T, Pawlikowska M, Pacuła AJ, Ścianowski J, Kozak W. The weakening effect of soluble epoxide hydrolase inhibitor AUDA on febrile response to lipopolysaccharide and turpentine in rat. J Physiol Biochem. 2017 Nov;73(4):551-560. doi: 10.1007/s13105-017-0584-y. Epub 2017 Jul 24. PubMed PMID: 28741242; PubMed Central PMCID: PMC5653702.
2: Dong XW, Jia YL, Ge LT, Jiang B, Jiang JX, Shen J, Jin YC, Guan Y, Sun Y, Xie QM. Soluble epoxide hydrolase inhibitor AUDA decreases bleomycin-induced pulmonary toxicity in mice by inhibiting the p38/Smad3 pathways. Toxicology. 2017 Aug 15;389:31-41. doi: 10.1016/j.tox.2017.07.002. Epub 2017 Jul 8. PubMed PMID: 28694203.
3: Xu J, Morisseau C, Yang J, Lee KSS, Kamita SG, Hammock BD. Ingestion of the epoxide hydrolase inhibitor AUDA modulates immune responses of the mosquito, Culex quinquefasciatus during blood feeding. Insect Biochem Mol Biol. 2016 Sep;76:62-69. doi: 10.1016/j.ibmb.2016.06.011. Epub 2016 Jun 28. PubMed PMID: 27369469; PubMed Central PMCID: PMC5010450.
4: Zhang J, Liu YS, Lu QH. Therapeutic effects of the soluble epoxide hydrolase (sEH) inhibitor AUDA on atherosclerotic diseases. Pharmazie. 2015 Jan;70(1):24-8. PubMed PMID: 25975094.
5: Diani-Moore S, Ma Y, Gross SS, Rifkind AB. Increases in levels of epoxyeicosatrienoic and dihydroxyeicosatrienoic acids (EETs and DHETs) in liver and heart in vivo by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and in hepatic EET:DHET ratios by cotreatment with TCDD and the soluble epoxide hydrolase inhibitor AUDA. Drug Metab Dispos. 2014 Feb;42(2):294-300. doi: 10.1124/dmd.113.055368. Epub 2013 Dec 5. PubMed PMID: 24311719; PubMed Central PMCID: PMC3912539.
6: Li J, Carroll MA, Chander PN, Falck JR, Sangras B, Stier CT. Soluble epoxide hydrolase inhibitor, AUDA, prevents early salt-sensitive hypertension. Front Biosci. 2008 May 1;13:3480-7. PubMed PMID: 18508449.
7: Dorrance AM, Rupp N, Pollock DM, Newman JW, Hammock BD, Imig JD. An epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol. 2005 Dec;46(6):842-8. PubMed PMID: 16306811; PubMed Central PMCID: PMC1444897.
